Gilead cash pile burns hole in investors' pockets
San Francisco
IN THE drug industry's biggest-ever period for deals, one wildly successful company with a multibillion-dollar war chest has been oddly silent. So what's Gilead Sciences Inc waiting for?
Drugmakers have done US$179 billion worth of mergers and acquisitions so far this year, on pace to top last year's US$221 billion record. Gilead has stayed on the sidelines, holding US$10.6 billion in cash and equivalents. The company reports second quarter earnings on Tuesday, and M&A will be on shareholders' minds.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices